Are your MRI contrast agents cost-effective? Learn more about generic Gadolinium-Based Contrast Agents.





This information is current as of April 18, 2024.

The efficacy of particulate embolization combined with stereotactic radiosurgery for treatment of large arteriovenous malformations of the brain.

J A Mathis, J D Barr, J A Horton, C A Jungreis, L D Lunsford, D S Kondziolka, D Vincent and S Pentheny

AJNR Am J Neuroradiol 1995, 16 (2) 299-306 http://www.ajnr.org/content/16/2/299

The Efficacy of Particulate Embolization Combined with Stereotactic Radiosurgery for Treatment of Large Arteriovenous Malformations of the Brain

John A. Mathis, John D. Barr, Joseph A. Horton, Charles A. Jungreis, L. Dade Lunsford, Douglas S. Kondziolka, Diana Vincent, and Susan Pentheny

PURPOSE: To evaluate the efficacy of combined particulate embolization and single-stage stereotactic radiosurgery in the treatment of large arteriovenous malformations (AVMs) of the brain. **METHODS:** Twenty-four patients with large brain AVMs (diameter >3.0 cm; volume > 14 cm³), who had previously undergone particulate embolization and stereotactic radiosurgery, were retrospectively evaluated 2 or more years after radiosurgery. **RESULTS:** In 12 (50%) of these patients there was complete AVM obliteration, comparing favorably with a 58% obliteration rate in a group of AVMs having a 4- to 10-cm³ volume, treated by radiosurgery alone. Recanalization of embolized, but not radiated, AVM segments was identified in 3 (12%) patients. However, long-term occlusion was demonstrated in the embolized portions of most AVMs subsequently treated by radiosurgery. Complications included 1 (4%) patient with a mild upper extremity paresis after radiosurgery and 2 (8%) patients with transient neurologic deficits after embolization. **CONCLUSION:** Combined embolization and stereotactic radiosurgery was more efficacious than radiosurgery alone for large brain AVMs. Recanalization after embolization did occur but was a relatively minor cause of treatment failure.

Index terms: Surgery, stereotactic; Interventional neuroradiology; Arteriovenous malformations, embolization

AJNR Am J Neuroradiol 16:299-306, February 1995

Stereotactic radiosurgery was pioneered in the early 1950s by Lars Leksell (1). The last 4 decades have seen a rapid proliferation of stereotactic radiosurgical technology. Currently used devices include the 201 source cobalt-60 gamma knife (2, 3), high-energy proton and heavy-ion charged-particle cyclotrons (4–8), and modified high-energy linear accelerators (9–11). The application of stereotactic radiosurgery to treat arteriovenous malformations (AVMs) of the brain began in the 1970s. Since that time, stereotactic radiosurgery has proved an effective alternative to microsurgery for selected brain AVMs (2–11).

Small AVMs (volume $< 4 \text{ cm}^3$) treated with stereotactic radiosurgery have a total obliteration rate of 80% to 88% 2 years after radiosurgery (3). However, equipment geometry and dose limitations diminish the obliteration rate of single-stage radiosurgery to 58% for AVM volumes between 4 and 10 cm³, with obliteration rates for AVMs greater than 10 cm³ falling to 28% (12). Documenting the effect of reducing large AVMs to a manageable size and thereby increasing treatment efficacy, Dawson et al reported encouraging results in a small group undergoing initial staged embolization before stereotactic radiosurgery when the AVM nidus exceeded 10 cm³ in volume (13).

From 1987 through 1992 at the University of Pittsburgh, 348 AVMs of the brain were treated with stereotactic radiosurgery. Fifty-six patients underwent preradiosurgical embolization; 24 of these met the criteria for inclusion in this study.

Received November 16, 1993; accepted after revision June 14, 1994. From the Division of Neuroradiology (J.A.M., J.D.B., J.A.H., C.A.J.,

D.V., S.P.) and the Department of Neurosurgery, (L.D.L., D.S.K.), University of Pittsburgh.

Address reprint requests to John M. Mathis, MD, MSC, Division of Neuroradiology–Endovascular Therapy, University of Virginia Health Sciences Center, Charlottesville, VA 22908.

AJNR 16:299–306, Feb 1995 0195-6108/95/1602–0299 © American Society of Neuroradiology

These criteria include preembolization and postembolization studies and a follow-up study 2 or more years after radiosurgery. This report evaluates the combination of staged particulate embolization and stereotactic radiosurgery in the long-term follow-up group of 24 patients.

Materials and Methods

Each patient received a diagnostic angiogram to determine the vascular supply to the AVM. Magnification images were obtained in at least two projections using rapidsequence imaging (four to six images per second). To allow accurate measurements corrected for magnification, radiopaque concentric sizing rings were affixed to the front, back, and sides of the head. Subsequent embolization was planned based on the diagnostic findings, with the goal of embolization being to reduce the size of the AVM to a 3.0-cm maximum diameter.

A Tracker-18 microcatheter (Target Therapeutics, Fremont, Calif) was introduced into the pedicle selected for embolization. Real-time digital fluoroscopic roadmapping was used for guidance. When positioned in a feeding pedicle, digital subtraction angiography was used to ensure that normal parenchyma was not also supplied. In addition, provocative testing was performed with a barbiturate (amobarbital or methohexital) administered through the microcatheter. The amount given was based on the type of barbiturate and the size of the pedicle being tested (14). A tailored neurologic examination immediately followed each barbiturate infusion.

Embolization was attempted only if the neurologic exam was unchanged from the baseline. The most common embolic agent was polyvinyl alcohol particles of various sizes ranging from 150 to 1000 μ m. In early cases silk suture was occasionally used for closure of large shunts within the AVM nidus that proved problematic with polyvinyl alcohol alone. Platinum microcoils were later used for fistulas or for final occlusion of a pedicle after polyvinyl alcohol embolization. Polyvinyl alcohol particles were suspended in nonionic contrast material for continuous visibility during embolization. Embolization was terminated when the pedicle was occluded or the flow was so slow that additional particulate embolization was hazardous because of possible reflux.

Hemodynamic changes during embolization require constant assessment to avoid embolization of cortical branches not filled on initial angiograms. Significant changes in the hemodynamics of a pedicle require a repeat of provocative testing (15).

Most embolizations were staged. Staged procedures are usually better tolerated by the patients and may reduce the risk of normal perfusion pressure breakthrough (16–18).

Diagnostic angiography was performed at the end of the embolization. The patients continued to receive corticosteroids for 48 hours. All patients were monitored in a neurologic intensive care unit after embolization. Stereotactic radiosurgery was performed 1 to 3 months after completion of staged embolization. A stereotactic headframe was affixed to the patient's head, and biplane angiography was performed, allowing coordinate calculation for subsequent stereotactic radiosurgery (19). Radiosurgery was performed as previously described (35).

After radiosurgery, interval follow-up was done with magnetic resonance imaging and angiography. Complete AVM resolution, suggested by magnetic resonance, was confirmed by angiography in all cases.

Results

Fifty-six patients with an initial AVM volume greater than 10 cm³ were referred for angiographic evaluation and staged embolization before stereotactic radiosurgery. Thirty-two of the 56 patients were excluded from this study because follow-up time was less than 2 years or because there were insufficient data to assess AVM size accurately before and after embolization and 2 or more years after radiosurgery.

All patients in this series whose AVMs were classified as totally obliterated after combined embolization and stereotactic radiosurgery underwent only single-stage radiosurgery. Patients in whom AVM obliteration was achieved after a second-stage radiosurgery procedure are presented as having had residual AVMs 2 years after the initial radiosurgery (considered incomplete obliteration in this study).

Twenty-four patients met all criteria for inclusion in this study (Table 1). Twelve (50%) AVMs were totally obliterated 2 years after radiosurgery. Seven (30%) patients had residual but smaller AVMs at 2 years. The remaining 5 (20%) patients had residual AVMs that had variable degrees of recurrence after embolization. Two of these patients' procedures were considered technical failures because of unrecognized external carotid feeders; the other 3 patients had recurrent AVM in the area of prior embolization, considered definite evidence of postembolization.

Two (8%) transient neurologic complications resulted from embolization (Table 1). In addition, one asymptomatic complication occurred from a fragment of catheter that detached and remained intraarterially located. This catheter fragment was surgically removed with no neurologic sequelas. One patient (4%) experienced hemiparesis 6 months after radiosurgery. This deficit largely resolved but the patient was left with permanent, mild right-hand weakness. No patients in this series experienced hemorrhage

AJNR: 16, February 1995

Case	AVM Location	Symptoms	Size before Embolization, cm (cm ³)	Size after Embolization, cm (cm ³)	Obliteration 2 yrs after Radiosurgery?	Complications
1	L parietal	Seizures	3.8 (29)	2.8 (11)	Yes	Hemiparesis after radiosurgery
2	L frontal	Seizures	3.2 (17)	2.4 (7.2)	Yes	None
3	R occipital	Seizure	5.1 (69)	3.2 (17)	Yes	None
4	R parietal	Seizure	3.5 (22)	3.0 (14)	Yes	None
5	L parietal	Hemorrhage	5.0 (65)	2.4 (7.2)	Yes	None
6	R parietal	Hemorrhage	3.0 (14)	1.7 (2.5)	Yes	None
7	L temporal	Headache	4.2 (39)	2.2 (5.5)	Yes	None
8	L parietal	Seizure	3.0 (14)	1.1 (.70)	Yes	None
9	R parietal	Hemorrhage	4.0 (34)	2.3 (6.4)	Yes	None
10	R basal ganglion	Hemorrhage	3.8 (29)	3.0 (14)	Yes	Catheter fragment after embolization
11	L occipital	Seizures	3.8 (29)	2.5 (8.2)	Yes	Transient visual field changes after embolization
12	R frontal	Headaches	3.5 (22)	2.4 (7.2)	Yes	None
13	L frontal	Seizures	4.8 (58)	3.6 (24)	No	None
14	R parietal	Hemorrhage	5.0 (65)	4.0 (34)	No	None
15	Cerebellar	Hemorrhage	5.5 (87)	4.4 (45)	No	None
16	R temporal	Seizure	6.0 (113)	4.5 (48)	No	None
17	R temporal	Headache	4.0 (34)	3.5 (22)	No	None
18	R frontal	Seizures	5.2 (74)	3.5 (22)	No	Transient R-hand paresthesia after embolization
19	R occipital	Seizure	3.9 (31)	2.3 (6.4)	No	None
20	Corpus callosum	Hemiparesis	3.0 (14)	1.8 (3.1)	No	None
21	L parietal	Seizures	4.3 (42)	2.4 (7.2)	No	None
22	L thalamic	Seizures	3.0 (14)	2.3 (6.4)	No	None
23	L parietal	Hemorrhage	5.0 (65)	3.3 (19)	No	None
24	L temporal	Hemorrhage	3.6 (24)	0.8 (.27)	No	None

TABLE 1: Combined embolization and radiosurgery for brain AVMs

after embolization or radiosurgery. There were no deaths (Table 2).

Discussion

Modern therapy for AVMs generally consists of (*a*) surgery alone, (*b*) surgery combined with preoperative embolization, or (*c*) stereotactic radiosurgery. Cases considered ideal for radiosurgery usually have maximum lesion diameters of less than 3.0 cm and have characteristics that would increase surgical risks (such as critical location, deep arterial supply, or central venous drainage). Primary radiosurgical treat-

TABLE 2: Complications of embolization and radiosurgery for brain AVMs

Neurologic Deficit	Radiosurgery	Embolization
Permanent	1 (4%) Mild	0
Transient	0	2 (8%)
Technical	0	1 (4%) (Catheter
		fragment)
Hemorrhage	0	0
Death	0	0

ment of AVMs larger than 3.0 cm in diameter requires reduction of the dose delivered to the AVM to maintain brain tolerance and minimize complications (20, 21). Dawson et al suggested that AVMs larger than 3.0 cm in diameter might be successfully treated with stereotactic radiosurgery if first reduced in size by embolization (13). The subsequent experience with combined embolization and stereotactic radiosurgery in the literature has been anecdotal, with no long-term follow-up available. Additionally, since the initial report by Dawson et al, there has been ongoing controversy regarding the best types of embolic material to use before radiosurgery, with the concern being that particulate embolization may be associated with an unacceptable risk of recanalization.

This series demonstrates that a single stereotactic radiosurgery successfully produced total AVM obliteration in 50% of patients with an initial AVM diameter larger than 3.0 cm when preceded by particulate embolization (Fig 1). In this study, a maximum single dimension was measured for each AVM. In preparation for ra-




Fig 1. A, Lateral projection of a right internal carotid artery angiogram reveals a frontal AVM with rapid venous shunting.

B, Superselective digital angiogram confirms the presence of a high-flow fistula (*arrowheads*).

C, Residual AVM after microcoil (arrow) and polyvinyl alcohol embolization.

D, Lateral projection of a right internal carotid artery angiogram 2 years after stereotactic radiosurgery shows total AVM obliteration.



diosurgery, the nonuniform geometry of the malformation is used to calculate the targeted volume. (For comparison, the approximate AVM volume has been included in parentheses, where the volume was estimated using the maximum AVM dimension as the diameter of a sphere.) In the successful treatment group, the average AVM size before embolization was 3.8 cm (29 cm³) and the average postembolization, preradiosurgical size was 2.4 cm (7.2 cm³), resulting in an average postembolization diam-

eter reduction of 37% (Table 3). Patients with residual AVM 2 years after radiosurgery had an average initial size of 4.4 cm (45 cm³) and postembolization size of 3.0 cm (14 cm³). These AVMs were typically larger and had a smaller effective diameter reduction associated with embolization (32%) (Fig 2). The statistical difference in the mean size of the total obliteration and residual AVM groups was found to be at the 0.5% and 0.1% levels for preembolization and postembolization diameters, respectively

		Ave		
AVM Outcome	Patients	Preembolization Diameter (Volume)	Postembolization Diameter (Volume)	Reduction in Diameter, %
Total obliteration	12 (50%)	3.8 cm (29 cm ³) (range, 3.0–5.1 cm)	2.4 cm (7.2 cm ³) (range, 1.2–3.2 cm)	37
Subtotal obliteration	12 (50%)	4.4 cm (45 cm ³) (range, 3.0–5.0 cm)	3.0 cm (14 cm ³) (range, 0.8–4.5 cm)	32
Embolization failures	5 (20%)			
Technical	2 (8%), unrecognized external feed			
Recanalization	3 (12%)			



Fig 2. Anteroposterior (*A*) and lateral (*B*) projections of a right vertebral angiogram show a vermian AVM before treatment.

Anteroposterior (*C*) and lateral (*D*) projections after particulate embolization reveal the residual AVM volume presented for stereotactic radiosurgery.

Anteroposterior (E) and lateral (F) images 2 years after radiosurgery demonstrates subtotal AVM obliteration.

(verified using Student's *t* test). These data show a total obliteration rate after combined embolization and radiosurgery of 50%, similar to the 58% total obliteration rate achieved in a group of initially smaller AVMs (2.0 to 2.7 cm diameter/4.2 to 10 cm³ volume) treated by single-stage radiosurgery alone. At this institution, AVMs greater than 2.7 cm diameter and treated by single-stage radiosurgery alone have shown only a 28% total obliteration rate. In this group of patients, there was a beneficial impact of embolization and AVM size reduction with a subsequent improved efficacy of single-stage radiosurgery in initially large AVMs.

In five patients with residual AVM at 2 years, embolizations were considered failures. In two (8%) of these patients, follow-up studies revealed external carotid artery feeders to the AVM that either had been undetected at the time of embolization or were subsequently recruited. Three (12%) additional patients had obvious recanalization of portions of the AVM that had been previously embolized (Fig 3). Recanalization after embolization is a well-described phenomenon, with the rate of recanalization related to the type of embolic agent, method of embolization, and type of vascular lesion (22-27). Liquid acrylics (ie, *N*-butyl 2-cyanoacrylate) have been presented as permanent embolic agents; however, recanalization has been noted with liquid embolic agents as well (22-25). Although recanalization after particulate embolization was noted in this series, it was demonstrated conclusively in only three (12%) patients, with an additional two (8%) patients having initially unrecognized (and untreated) supply from external carotid artery branches. This recanalization rate compares favorably with revascularization with liquid adhesive embolization as reported by Fournier et al (23). In their report of 49 AVMs embolized with liquid adhesive, they subsequently found that in eight (16.3%) patients a newly formed dural supply developed and in six (12.2%) patients there was revascularization via intracranial collaterals.

In our series, one (4%) permanent neurologic deficit occurred after stereotactic radiosurgery, leaving the patient with a mild residual right-



Fig 3. *A*, Anteroposterior angiogram shows the pretreatment AVM configuration.

B, The angiogram shows the residual AVM after embolization. The area designated *E* presents the embolized portion of the AVM.

C, Follow-up angiogram 2 years after stereotactic radiosurgery reveals recanalization of AVM in the previously embolized region. (The area designated *GK* represents the gamma knife volume.)

D, Three years after stereotactic radiosurgery the volume treated by radiosurgery remains obliterated.

hand weakness. This is consistent with the 4.4% complication rate in our overall experience with stereotactic radiosurgery for brain AVMs (3). It is also similar to the 3% complication risk predicted by the integrated logistic formula used to

help select an allowable dose for a given AVM volume (21). Using helium-ion beam radiosurgery, Steinberg et al initially experienced a 50% complication rate in AVMs with diameters greater than 3 cm and doses greater than 18 Gy (8). Complications were subsequently decreased by a reduction in dose delivered (28). This result highlights the need to minimize the overall dose in large AVMs if a low complication rate is to be maintained.

There were no permanent neurologic complications associated with embolization in this series. However, 2 (8%) patients did have transient deficits that completely resolved. Also, a detached catheter fragment required vertebral arteriotomy and surgical removal; this event occurred without neurologic sequela. This rate of complication is consistent with that from other reports (24, 27, 29-31) (Table 4). The degree to which the AVM size is diminished may correlate with the incidence of complications just as does AVM location, number of feeders, and initial AVM size. Our goal was to achieve only an adequate size reduction (<3 cm in diameter) to allow acceptable radiosurgical coverage. When this target size was reached, we refrained from further attempts at embolization and therefore possibly avoided additional complications, even though additional AVM size reduction below the 3-cm target goal may ultimately prove desirable because of additional increased radiosurgical efficacy. Five of the 12 patients with AVMs not obliterated 2 years after radiosurgery had AVM diameters less than 2.5 cm after embolization (Table 1). This suggests that size is not the sole determinant of AVM response to stereotactic radiosurgery.

Postoperative complication rates after resection of large AVMs range from 14% to 24% in recently reported series (33, 34). Mortality rates range from 0% to 3.6%. In each of these surgical series, complications increase significantly as

TABLE 4: Complications associated with embolization

Series (Reference)	Patients	Embolic Agent	Transient	Permanent	Death	Technical
Present study	24	PVA	2 (8%)	0	0	1 (4%)
Purdy (27)	39	PVA	3 (8%)	2 (5%)	1 (3%)	2 (5%)
Pasqualin (29)	49	Silastic	5 (9.8%)	0	0	0
Viñuela (30)	101	IBCA/PVA	?	13 (12.9%)	1 (0.9%)	3 (2.9%)
Fournier (24)	49	IBCA	8 (16%)	4 (8%)	0	0
Nakstad (31)	20	PVA	1 (5%)	1 (5%)	0	0

Note.-PVA indicates polyvinyl alcohol; and IBCA, isobutyl cyanoacrylate.




Fig 4. Flow chart shows the treatment plan of our 24 patients.

the size and Spetzler-Martin grade (32) of the AVM increases. Although there remains a latent period between radiosurgical treatment and AVM obliteration (with a portion of patients requiring a repeat treatment), the complication rate and lack of hemorrhage in this group of patients who underwent combined embolization and stereotactic radiosurgery is encouraging when compared with figures reported from surgical removal of large AVMs. Patients with AVMs that are not totally obliterated at 2 years after radiosurgery are considered candidates for repeat radiosurgery. One of our patients who underwent a second stereotactic radiosurgery has progressed to total AVM obliteration. Others in this group await repeat radiosurgery or have already been retreated (Fig 4).

Conclusions

In this evaluation, there was a benefit to embolization and AVM size reduction: they improved the efficacy of single-stage radiosurgery for the treatment of initially large AVMs. This improvement was achieved with a relatively low complication rate.

Embolization failures and recanalizations did occur after particulate embolization, but these results were similar to those reported with liquid adhesives. Additional evaluation, with direct comparison between long-term follow-up results of particulate and liquid embolic agents used in combination with stereotactic radiosurgery, is needed. The combined therapeutic approach of embolization and stereotactic radiosurgery for large brain AVMs offers an additional treatment alternative when the risk of surgical resection is too high or surgery is unacceptable to the patient.


References

- 1. Leksell L. Stereotaxis and Radiosurgery: An Operative System. Springfield, Ill: Charles C. Thomas, 1951
- Steiner L. Radiosurgery in cerebral arteriovenous malformations. In: Flamm E, Fein J, eds. *Textbook of Cerebrovascular Surgery,* vol 4. New York: Springer-Verlag, 1986:1161–1215
- Lunsford LD, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for arteriovenous malformations of the brain. J Neurosurg 1991;75:512–524
- Kjellberg RN, Hanamura T, Davis KR, Lyons SL, Adams RD. Bragg-peak proton-beam therapy for arteriovenous malformations of the brain. N Engl J Med 1983;309:269–274
- Fabrikant JI, Lyman JT, Hosobuchi Y. Stereotactic heavy-ion Bragg peak radiosurgery for intra-cranial vascular disorder: method for treatment of deep arteriovenous malformations. Br J Radiol 1984;57:479–490
- Hosobuchi Y, Fabrikant J, Lyman J. Stereotactic heavy particle irradiation of intracranial arteriovenous malformations. *Appl Neu*rophysiol 1987;50:248–252
- Levy RP, Fabrikant JI, Frankel KA, Phillips MH, Lyman JT. Stereotactic heavy-charged-particle Bragg peak radiosurgery for the treatment of intracranial arteriovenous malformations in childhood and adolescence. *Neurosurgery* 1989;24:841–851
- Steinberg GK, Fabrikant JI, Marks MP, et al. Stereotactic heavy charged-particle Bragg peak radiation for intracranial arteriovenous malformations. N Engl J Med 1990;323:96–101
- Colombo F, Benedetti A, Pozza F, Marchetti C, Chieregi G. Linear accelerator radiosurgery of cerebral arteriovenous malformations. *Neurosurgery* 1989;24:833–839


306 MATHIS

- Betti OO, Munari C, Rosler R. Stereotactic radiosurgery with the linear accelerator: treatment of arteriovenous malformations. *Neurosurgery* 1989;24:311–321
- Loeffler JS, Alexander E, Disson RL, Saunders WM, Coleman CN, Winston KR. Stereotactic radiosurgery for intracranial arteriovenous malformation using a standard linear accelerator. *Int J Radiat Oncol Biol Phys* 1989;17:673–677
- Lunsford LD, Kondziolka D, Bissonete DJ, Maitz AH, Flickinger JC. Stereotactic radiosurgery of brain vascular malformations. *Neurosurg Clin N Am* 1992;3:79–98
- Dawson RC, Tarr RW, Hecht ST, et al. Treatment of arteriovenous malformations of the brain with combined embolization and stereotactic radiosurgery. *AJNR Am J Neuroradiol* 1990;11:857– 864
- Barr JD, Mathis JM, Horton JA. Provocative pharmacological testing during arterial embolization. *Neurosurg Clin N Am* 1994; 5(3):403–411
- 15. Rauch RA, Viñuela F, Dion J, et al. Pre-embolization functional evaluation in brain arteriovenous malformations: the selective amytal test. *AJNR Am J Neuroradiol* 1992;13:303–308
- Andrews BT, Wilson CB. Staged treatment of arteriovenous malformations of the brain. *Neurosurgery* 1987;21(3):314–323
- Halbach VV, Higashida RT, Hieshima GB, Norman D. Normal perfusion pressure breakthrough occurring during treatment of carotid and vertebral fistulas. *AJNR Am J Neuroradiol* 1987;8: 751–756
- Batjer HH, Purdy PD, Giller CA, Samson DS. Evidence of redistribution of cerebral blood flow during treatment for an intracranial arteriovenous malformation. *Neurosurgery* 1989;25(4):599–605
- Sadler LR, Jungreis CA, Lunsford LD, Trapanotto MM. Angiographic technique to precede gamma knife radiosurgery for intracranial arteriovenous malformations. *AJNR Am J Neuroradiol* 1990;11:1157–1161
- Flickinger JC, Lunsford LD, Kondziolka D. Dose prescription and dose-volume effects in radiosurgery. *Neurosurg Clin N Am* 1992; 3:51–59
- Flickinger JC, Schell MC, Larson DA. Estimation of complications for linear accelerator radiosurgery with the integrated logistic formula. *Int J Radiat Oncol Biol Phys* 1990;19:143–148
- Vinters HV, Lundie MJ, Kaufman JC. Long-term pathological follow-up of cerebral arteriovenous malformations treated by embolization with bucrylate. N Engl J Med 1986;314:477–483

- Viñuela F, Fox AJ, Pelz D. Angiographic follow-up of large cerebral AVMs incompletely embolized with isobutyl 2-cyanoacrylate. *AJNR Am J Neuroradiol* 1986;7:919–925
- Fournier D, TerBrugge KG, Willinsky R, LasJaunias P, Montanera W. Endovascular treatment of intracerebral arteriovenous malformations: experience in 99 cases. J Neurosurg 1991;75:228–233
- Rao VR, Madalam KR, Gupta AK, Kumar S, Joseph S. Dissolution of isobutyl 2-cyanoacrylate on long-term follow-up. AJNR Am J Neuroradiol 1989;10:135–141
- Germano IM, Davis RL, Wilson CB, Hieshima GB. Histopathological follow-up study of 66 cerebral arteriovenous malformations after therapeutic embolization with polyvinyl alcohol. *J Neurosurg* 1992;76:607–614
- Prudy PD, Samson D, Batjer HH, Risser RC. Preoperative embolization of cerebral arteriovenous malformations with polyvinyl alcohol particles: experience in 51 adults. *AJNR Am J Neuroradiol* 1990;11:501–510
- Malik GM, Umansky F, Patel S. Microsurgical removal of arteriovenous malformations of the basal ganglia. *Neurosurgery* 1988; 23:209–217
- Pasqualin A, Scienza R, Cioffi F, et al. Treatment of cerebral arteriovenous malformations with a combination of preoperative embolization and surgery. *Neurosurgery* 1991;29:358–367
- Viñuela F, Dion JE, Duckwiler G, et al. Combined endovascular embolization and surgery in the management of cerebral arteriovenous malformations: experience with 101 cases. *J Neurosurg* 1991;75:856–864
- Nakstad PH, Bakke SJ, Hald JK. Embolization of intracranial arteriovenous malformations and fistulas with polyvinyl alcohol particles and platinum fiber coils. *Neuroradiology* 1992;34:348– 351
- Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg 1986;65:476–483
- Morgan MK, Johnston IH, Hallinan JM, Weber NC. Complications of surgery for arteriovenous malformations of the brain. *J Neuro*surg 1993;78:176–182
- Heros RC, Korosuek K, Diebold PM. Surgical excision of cerebral arteriovenous malformations: late results. *Neurosurgery* 1990;26: 570–578
- Lundsford LD, Flickenger J, Lindner G, et al. Stereotactic radiosurgery of the brain using the first United States 201 cobalt-60 source gamma knife. *Neurosurgery* 1989;24:151–159



.



E

Ŧ

